GlassScriptPhysician profile
Ernest P De Leon
NPI 1558454603
$14,549.20
in general payments reported to CMS, 2019-2025
57 companies · $1,684 in 2025
The $1,684 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,461 · 2020: $1,840 · 2021: $2,124 · 2022: $2,208 · 2023: $2,126 · 2024: $2,107 · 2025: $1,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,832 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,831.74 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,324.37 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,300.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,061.86 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $888.41 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $868.83 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Janssen Pharmaceuticals, INC | $761.68 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $476.43 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $453.56 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Amgen INC. | $446.07 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $398.09 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $383.10 | 2019-2022 | |
| Glaxosmithkline, LLC. | $345.65 | 2019-2024 | Trelegy Ellipta |
| Neurelis, INC. | $331.21 | 2022-2025 | Valtoco |
| Allergan, INC. | $264.14 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $258.55 | 2019-2023 | Seglentis, Livalo |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest De Leon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.